US Pharma MarketingAfter prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US nod
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light in the U.S. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing…
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light in the U.S.
Source: FiercePharma